From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin
Condition
Observations
Treatment
Hypertension
1
UP446 250 mg
Varicose veins
Fluid in knee
Reduced flexibility
Placebo
Psoriasis
2
UP446 250 and 500 mg